ImmunoPrecise Antibodies Ltd. , a leader in AI-driven biotherapeutic research and technology, is excited to announce a new use case for the Information Integration Dilemma solution developed by its. | June 13, 2023
ImmunoPrecise Antibodies Ltd. today introduced a transformative AI-driven rapid therapeutic screening platform, the result of a collaboration between IPA Canada and its subsidiary, BioStrand®.. | June 6, 2023
ImmunoPrecise Antibodies Ltd. , an AI-driven biotherapeutic research and technology company, today announced that its subsidiary, BioStrand®, has successfully solved the Information Integration. | May 30, 2023